GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that
researchers will present eight abstracts from its respiratory disease program
at the Annual Meeting of the American Thoracic Society, from May 18 to 20,
2008 in Toronto, Canada. Presentations are designed to showcase MedImmune's
biologics capabilities.
"MedImmune is committed to finding innovative solutions that may one day
help patients struggling with respiratory diseases," said Tony Coyle, vice
president, head, autoimmunity inflammation and respiratory disease research.
"We are pleased to present a plethora of promising data that could potentially
address diseases such as asthma and chronic obstructive pulmonary disease."
MedImmune research scheduled to be presented includes:
-- Regulation of Lung Inflammation in Animal Models (Poster Session:
IL-33, the Ligand for T1/ST2, Induces Airway Hyperresponsiveness Via a
Mast Cell but Not T Cell Dependent Mechanism, publication page A63)
- Sunday, May 18 from 8:15 a.m.- 4:15 p.m., Metro Toronto Convention
Centre, Area E.
-- Viral Infection and Wheezing (Poster Session: Evidence for T-Lymphocyte
Independent Antibody Responses in Primary RSV Infection, publication
page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 p.m., Metro Toronto
Convention Centre, Area A.
-- Chitins: Flying High (Symposium: Hyperresponsiveness and Inflammation
in a Murine Model of Asthma, publication page A501)- Monday, May 19 at
2:45 p.m., Ontario, Fairmont Royal York Hotel.
-- New Insights and Developing Controversies in Clinical Asthma (Poster
Session: Safety Profile, Pharmacokinetics and Biologic Activity of a
Single IV Dose of the Anti IL-5 Receptor Alpha Antibody MEDI-563 in
Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from
8:15 a.m.- 11:00 a.m., Metro Toronto Convention Centre, Room 205A.
-- Eosinophils, Mast Cells and Neutrophils as Modulators of Immunity and
Injury
-- Poster Session: In Vitro Characterization of MEDI-563, a Humanized
Anti-IL-5Ralpha Monoclonal Antibody in Phase1 Clinical Trial,
publication page A602
-- Poster Session: MEDI-563, a Humanized Anti-Human IL-5R alpha Antibody
Binds to Lung Tissue Eosinophils in Asthmatic Patients, publication
page A602
-- Poster Session: A Monoclonal Anti-IL-5 Receptor (IL-5R) alpha
Antibody with Enhanced ADCC Selectively and Efficaciously Depletes
Tissue Eosinophils in IL-5 Transgenic Mice, publication page A603
The preceding presentations will occur on Tuesday, May 20 from
8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
-- Monocytes and Macrophages in Inflammation, Immunity and Injury (Poster
Session: Role for Alveolar Macrophages in Limiting Primary RSV
Immunopathology, publication page A623) - Tuesday, May 20 from 8:15
a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.
About MedImmune
MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and
is the worldwide biologics business for the AstraZeneca Group. The company
has approximately 3,000 employees worldwide and is headquartered in
Gaithersburg, Maryland. MedImmune strives to provide better medicines to
patients, new medical options for physicians and rewarding careers to
employees. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on infection, oncology, respiratory
disease and inflammation, cardiovascular/gastrointestinal disease and
neuroscience. For more information, visit MedImmune's website at
www.medimmune.com.
SOURCE MedImmune
CONTACT: Media: Sidoney Atse, +1-301-398-5990, or Investors: Peter
Vozzo, +1-301-398-4358, both of MedImmune